Crestor Cost in Wyoming 2026: Prices, Insurance, and Savings Options

What Does Crestor Actually Cost in Wyoming Right Now?

The price gap between brand-name Crestor and generic rosuvastatin in Wyoming is dramatic. Brand Crestor carries a manufacturer list price of $290 per month from AstraZeneca, while the average cash price for generic rosuvastatin at Wyoming retail pharmacies sits around $15 per month in 2026. That is a 95% difference.

Wyoming has approximately 200 retail pharmacies spread across the state, and pricing can vary by location. Pharmacies in Cheyenne, Casper, and Laramie tend to cluster near the $15 average, though rural locations may charge slightly more due to distribution costs. Chain pharmacies like Walmart, Walgreens, and Albertsons typically offer the lowest generic cash prices, often through their own discount formulary programs. Independent pharmacies may price slightly higher but can sometimes match or beat chain prices when asked directly. The FDA-approved prescribing information for rosuvastatin lists doses from 5 mg to 40 mg, and the generic price at most Wyoming pharmacies holds relatively steady across dose strengths for the standard tablet formulation.

Patients who fill a 90-day supply rather than monthly refills can sometimes negotiate an even lower per-unit cost. A 90-day generic rosuvastatin prescription filled at a major chain pharmacy in Wyoming may run $30 to $40 total, effectively reducing the monthly cost to $10 to $13.

Wyoming Medicaid and Crestor Coverage

Wyoming Medicaid does not cover brand-name Crestor. The state's preferred drug list (PDL) includes generic rosuvastatin, but the brand formulation requires prior authorization that is rarely approved given the availability of therapeutically equivalent generics.

For Wyoming Medicaid enrollees, generic rosuvastatin is typically available at $0 to $3 per prescription, depending on the managed care organization handling pharmacy benefits. Wyoming operates a fee-for-service Medicaid program for most beneficiaries, and generic statins fall into the lowest copay tier. The 2018 ACC/AHA cholesterol guideline designates high-intensity statin therapy (rosuvastatin 20 to 40 mg) as first-line treatment for patients with established atherosclerotic cardiovascular disease (ASCVD), making coverage denials for the generic uncommon.

Wyoming expanded Medicaid eligibility in 2024, adding approximately 19,000 adults to the rolls. Many of these new enrollees are between ages 40 and 64, a population with significant statin eligibility based on 10-year ASCVD risk calculation. If you are a new Medicaid enrollee in Wyoming and need a statin, your prescriber should write for generic rosuvastatin rather than brand Crestor to avoid the prior authorization process entirely.

Dual-eligible patients (those with both Medicare and Medicaid) in Wyoming receive statin coverage through their Medicare Part D plan, not through Medicaid pharmacy benefits. Part D plans in Wyoming generally cover generic rosuvastatin at Tier 1 with copays ranging from $0 to $10 per month.

Insurance Coverage for Crestor and Rosuvastatin in Wyoming

Most commercial insurance plans available in Wyoming cover generic rosuvastatin on Tier 1 of their formularies, meaning the lowest copay bracket. Brand Crestor, by contrast, typically falls on Tier 3 (preferred brand) or is excluded entirely, requiring the patient to pay the full $290 or submit a formulary exception request.

Wyoming's individual market is served by Blue Cross Blue Shield of Wyoming and a small number of additional carriers through the federal exchange. All Affordable Care Act (ACA) marketplace plans are required to cover at least one statin in each intensity category, and generic rosuvastatin satisfies the high-intensity requirement. Employer-sponsored plans in Wyoming follow a similar pattern. A 2022 analysis in JAMA Network Open found that formulary placement of generic statins on the lowest copay tier was associated with a 15% increase in medication adherence compared to plans requiring higher cost-sharing.

For patients whose physicians specifically prescribe brand Crestor rather than the generic (a rare clinical scenario), filing a formulary exception requires documentation that the patient has tried and failed generic rosuvastatin. Given bioequivalence between the brand and generic, insurers in Wyoming approve these exceptions infrequently.

Self-funded employer plans, which cover a significant portion of Wyoming's privately insured workforce, set their own formularies. These plans nearly always prefer generic rosuvastatin and may not cover brand Crestor at all.

Is Compounded Rosuvastatin Legal in Wyoming?

Yes. Compounded rosuvastatin is available through licensed 503A compounding pharmacies operating in Wyoming. These pharmacies may compound rosuvastatin into alternative dosage forms (liquid suspensions, custom-dose capsules) for patients who cannot swallow standard tablets or who require a dose not commercially available.

Under FDA guidance on 503A compounding, a 503A pharmacy may compound a prescription for an individual patient based on a valid prescription from a licensed prescriber, provided the compounded product is not essentially a copy of a commercially available drug. This means a 503A pharmacy in Wyoming can legally compound rosuvastatin into a suspension for a pediatric patient with familial hypercholesterolemia, but it cannot simply replicate the standard 10 mg or 20 mg tablet that is already commercially available at $15 per month.

Wyoming follows the FDA's compounding framework without adding additional state-level restrictions that would block 503A access. The Wyoming Board of Pharmacy licenses and inspects compounding pharmacies operating within the state. Patients seeking compounded rosuvastatin should confirm that their pharmacy holds a current 503A registration.

Pricing for compounded rosuvastatin varies by pharmacy and formulation. Some HealthRX-affiliated compounding pharmacies offer compounded formulations at no additional cost beyond the consultation fee, while traditional compounding pharmacies in Wyoming may charge $20 to $50 per month depending on the preparation.

How Rosuvastatin Stacks Up Clinically: The Evidence Behind the Price

Rosuvastatin is the most potent statin on the market by milligram. At 40 mg, it reduces LDL cholesterol by approximately 55%, compared to 47% for atorvastatin 80 mg, according to data from the STELLAR trial. This potency distinction matters clinically for patients who need aggressive LDL lowering.

The JUPITER trial (N=17,802) randomized apparently healthy individuals with LDL cholesterol <130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP ≥ 2 mg/L) to rosuvastatin 20 mg or placebo. The trial was stopped early at a median 1.9 years because of a 44% relative risk reduction in the primary composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death (HR 0.56 to 95% CI 0.46 to 0.69, P<0.00001). NNT over 5 years was 25.

The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol recommends high-intensity statin therapy (rosuvastatin 20 to 40 mg daily) for four specific patient groups: those with clinical ASCVD, those with LDL ≥ 190 mg/dL, adults aged 40 to 75 with diabetes and LDL ≥ 70 mg/dL, and adults aged 40 to 75 with a 10-year ASCVD risk ≥ 7.5%. Dr. Scott Grundy, lead author of the guideline, stated: "High-intensity statin therapy is the foundation of ASCVD risk reduction, and generic availability has removed cost as a barrier for most patients."

For Wyoming residents, the clinical strength of rosuvastatin combined with its low generic price makes it one of the highest-value prescriptions in cardiovascular medicine. A medication that costs $15 per month and reduces heart attack and stroke risk by 44% in the right patient population represents an exceptional return on healthcare spending.

Telehealth Prescribing of Rosuvastatin in Wyoming

Wyoming permits telehealth prescribing of rosuvastatin. No in-person visit is required to initiate or maintain a statin prescription through a licensed telehealth provider.

Wyoming enacted permanent telehealth parity legislation (SF 54) that requires insurers to cover telehealth visits at the same rate as in-person visits. This applies to both initial prescribing and ongoing management of statin therapy. A prescriber licensed in Wyoming (or holding a Wyoming telemedicine license) can evaluate a patient's lipid panel, calculate 10-year ASCVD risk, and prescribe rosuvastatin without the patient ever visiting a brick-and-mortar clinic.

This is particularly relevant in a state like Wyoming, where the population density is the lowest in the nation at 5.8 people per square mile. Many residents live 60 or more miles from the nearest primary care physician. Telehealth removes the geographic barrier that might otherwise delay initiation of statin therapy. The USPSTF recommends statin therapy for adults aged 40 to 75 with at least one cardiovascular risk factor and a 10-year ASCVD risk of 10% or greater, making telehealth a practical pathway for reaching patients in rural Wyoming counties like Sublette, Niobrara, and Hot Springs.

HealthRX offers telehealth-based rosuvastatin prescribing for Wyoming residents. The process involves submitting recent lab work (lipid panel drawn within the past 12 months), completing a medical intake, and having a provider review and prescribe. Most patients receive their prescription within 24 to 48 hours of completing the intake.

Discount Programs and Savings Strategies for Wyoming Patients

Several discount pathways can reduce rosuvastatin costs for Wyoming residents who are uninsured or underinsured.

Manufacturer savings cards. AstraZeneca historically offered a Crestor savings card that reduced brand copays for commercially insured patients. With the brand now off-patent, these programs have limited applicability. Generic manufacturers do not typically offer savings cards because the cash price is already low.

Pharmacy discount programs. Walmart's $4/$10 generic program includes rosuvastatin at select doses. Costco Pharmacy (available in Cheyenne) often prices generic rosuvastatin below $10 for a 30-day supply. Mark Cuban's Cost Plus Drugs lists generic rosuvastatin at manufacturer cost plus a flat markup and shipping fee, which can undercut local pharmacy pricing for patients willing to receive medication by mail.

GoodRx and similar aggregators. Coupon aggregators can bring the price of generic rosuvastatin below $10 per month at participating Wyoming pharmacies. These coupons are free to use but do not count toward insurance deductibles.

Patient assistance programs. For the rare patient who requires brand Crestor specifically, AstraZeneca's AZ&Me patient assistance program provides the medication at no cost to qualifying uninsured patients with household incomes below 300% of the federal poverty level. The FDA's resource page on drug assistance links to additional programs.

340B pharmacies. Wyoming has several federally qualified health centers (FQHCs) and critical access hospitals participating in the 340B Drug Pricing Program. Eligible patients who receive care at these facilities can access rosuvastatin at significantly reduced prices, sometimes $0 per month.

Safety Monitoring and Dose Considerations in Wyoming

Rosuvastatin requires periodic lab monitoring regardless of where you fill the prescription. The ACC/AHA guideline recommends a fasting lipid panel 4 to 12 weeks after starting therapy and every 3 to 12 months thereafter. Liver function tests (ALT) should be checked at baseline, with repeat testing only if symptoms of hepatotoxicity develop.

Asian-American patients should be started at rosuvastatin 5 mg due to pharmacokinetic differences that increase drug exposure by approximately twofold, per the FDA-approved labeling. Patients with severe renal impairment (eGFR <30 mL/min) should not exceed 10 mg daily.

Common side effects include myalgia (reported in 2% to 11% of patients across clinical trials), headache, and nausea. Rhabdomyolysis is rare, occurring at a rate of approximately 1 per 100,000 patient-years according to a Cochrane review of statin safety. Patients experiencing unexplained muscle pain, tenderness, or weakness should report symptoms promptly rather than stopping the medication on their own.

Wyoming's altitude (mean elevation 6,700 feet) and outdoor-activity culture mean patients commonly ask whether statins affect exercise performance. A 2013 study in the Journal of the American College of Cardiology found that statin therapy did not reduce aerobic fitness gains during a structured exercise program, though individual responses vary. Patients who experience exercise-related muscle symptoms on rosuvastatin may benefit from switching to a lower dose or alternate-day dosing, though this should be discussed with their prescriber.

Rosuvastatin 20 mg daily costs $15 per month in Wyoming, reduces LDL cholesterol by approximately 50%, and cut major cardiovascular events by 44% in the JUPITER population over 1.9 years of follow-up.